Ameliorating TIMM50 Loss Slows Senescence by Improving Mitochondrial Structure and Function

Area of Science:

• Cellular Biology
• Mitochondrial Biology
• Aging Research

Background:

• Mitochondrial dysfunction, characterized by increased volume, reduced Adenosine Triphosphate (ATP) production, and elevated Reactive Oxygen Species (ROS), is a key feature of cellular senescence and aging.
• Existing research links dysfunction to Electron Transport Chain (ETC) issues, low NAD levels, and impaired mitophagy, but the genetic underpinnings remain unclear.

Purpose of the Study:

• To investigate the genetic regulation of mitochondrial dysfunction in cellular senescence.
• To identify novel mitochondrial proteins involved in the senescence pathway.

Main Methods:

• Utilized multiple senescence models to study the role of Translocase of Inner Mitochondrial Membrane 50 (TIMM50).
• Assessed mitochondrial function using various assays to characterize the impact of TIMM50 downregulation.
• Performed pathway analysis to elucidate the regulatory mechanism of TIMM50 expression.
• Screened anti-aging compounds for their effect on TIMM50 stability and senescence.

Main Results:

• Demonstrated that downregulation of TIMM50 is sufficient to trigger cellular senescence by impairing mitochondrial function.
• Showed that reduced TIMM50 levels initiate senescence hallmarks, while TIMM50 overexpression delays senescence onset.
• Identified a pathway where sirtuin1-dependent downregulation of CCAAT enhancer binding protein alpha (CEBPα) leads to TIMM50 loss.
• Found that verapamil and MitoTEMPO stabilize TIMM50 and delay senescence.

Conclusions:

• Identified TIMM50 as a critical mitochondrial protein whose reduced expression initiates cellular senescence.
• Established TIMM50 downregulation as a key step in the aging process.
• Highlighted verapamil and MitoTEMPO as potential therapeutic agents for age-related decline by targeting TIMM50.